Liraglutide exhibits anti-inflammatory activity through the activation of the PKA/CREB pathway

Abstract

Qihong Que and colleagues found that liraglutide exhibited anti-inflammatory activity through the activation of the PKA/CREB pathway in an OA rat model. We believe there was a flaw in this research. In their first experiment, the sacrifice time of the 10 rats in the control group has not been stated. And when the rats in the OA-1, OA-5, OA-10, OA-20 and OA-28 groups were sacrificed, they were in different weeks of age. If the rats in the control group were compared to the rats in the OA-1, OA-5, OA-10, OA-20 and OA-28 groups respectively, the results may be biased due to differences in the week age of the rats. We believe that addressing this issue could further increase the value of their study.

Emerging insights into the role of IL-1 inhibitors and colchicine for inflammation control in type 2 diabetes

“…Glucagon-like peptide-1 (GLP-1) receptor agonists, such as liraglutide and exenatide, have been shown to exert anti-inflammatory effects [ 174 , 175 ]. These drugs enhance insulin secretion and inhibit glucagon release, improving glycemic control.…”